STOCK TITAN

Horizon Technology Finance Corporation - HRZN STOCK NEWS

Welcome to our dedicated page for Horizon Technology Finance Corporation news (Ticker: HRZN), a resource for investors and traders seeking the latest updates and insights on Horizon Technology Finance Corporation stock.

Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company headquartered in Farmington, Connecticut. The company is dedicated to providing capital in the form of structured debt products to venture capital-backed companies across the technology, life sciences, healthcare information and services, and sustainability industries. Since its inception in 2004, Horizon has successfully originated and invested more than $1.2 billion in venture loans to over 200 burgeoning companies.

Horizon operates with the primary objective of maximizing its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives. The company's experienced team of investment professionals brings a wealth of industry knowledge, ensuring reliable and forward-looking capital solutions to its portfolio companies. Horizon's strong relationships within the venture capital community enable it to support its clients in bridging financial gaps and overcoming growth challenges.

Recent achievements highlight Horizon's robust financial performance. For the fourth quarter of 2023, Horizon reported a 21.8% increase in total investment income, reaching $28.2 million. The company's dollar-weighted annualized yield on average debt investments was 16.8%, reflecting its strategic focus on high-yield opportunities. Horizon's portfolio at the end of 2023 consisted of 56 secured loans, amounting to a fair value of $670.2 million, and total warrant, equity, and other investments in 102 companies valued at $38.9 million.

Horizon continues to actively manage its investments, prudently growing its portfolio and maximizing net asset value (NAV). Despite market challenges, including some unrealized depreciation on investments, the company remains committed to supporting its borrowers and maximizing capital recovery. As of December 31, 2023, Horizon's net assets stood at $324.0 million, or $9.71 per share.

In addition to its financial achievements, Horizon announced a significant acquisition through its affiliate HIMV LLC. Horizon facilitated the acquisition of a comprehensive portfolio of discovery, preclinical, and clinical stage assets from IMV Inc., aiding BioVaxys Technology Corp. in integrating these assets and expanding its clinical-stage programs.

Looking ahead, Horizon is set to release its financial results for the fourth quarter of 2023 on February 27, 2024, and will host a conference call to discuss these results. The company's board of directors has also declared monthly distributions of $0.11 per share for April, May, and June 2024, and a special distribution of $0.05 per share in April 2024.

Horizon Technology Finance Corporation remains a pivotal player in the venture lending landscape, offering substantial value and unwavering support to its portfolio companies. To learn more, visit horizontechfinance.com.

Rhea-AI Summary
BioVaxys Technology Corp. completes the acquisition of IMV Inc.'s assets, expanding its portfolio in oncology, infectious disease, allergy desensitization, and autoimmune diseases. The acquisition includes clinical-stage programs like Maveropepimut-S, with plans for organic growth through licensing and partnership opportunities. The Company aims to leverage the DPX™ and HapTenix© platforms for targeted immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
-
Rhea-AI Summary
Horizon Technology Finance Corporation (HRZN) plans to release financial results for Q4 2023 on February 27, 2024. The conference call to discuss the results will be held on February 28, 2024, featuring key executives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Summary
BioVaxys Technology Corp. acquires IMV's extensive technology portfolio through an Asset Purchase Agreement, including the DPX™ immune educating platform. The transaction involves upfront cash payment, milestone payments, royalties, and shares of BioVaxys common stock. BioVaxys gains access to DPX™ antigen delivery platform for cancer immunotherapies, specifically maveropepimut-S. The acquisition includes patents, patent applications, international filings, trademarks, and intellectual property. BioVaxys aims to expand its pipeline in oncology, infectious diseases, and immunological fields, positioning itself as a key player in cancer immunotherapy and other verticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
Rhea-AI Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) originated $63.4 million of new loans in Q4, ending 2023 with a committed backlog of $218 million. The portfolio update for the fourth quarter ended December 31, 2023, includes significant originations, liquidity events, partial paydowns, principal payments received, commitments, pipeline and term sheets, and details about the warrant and equity portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Summary
Parse Biosciences (HRZN) secures $50 million in financing to expand single cell sequencing solutions and serve academic, biotech, and pharma customers. The funding, led by Soleus Capital, will drive the company's product portfolio and commercial reach, bringing total funding to over $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) has declared monthly cash distributions of $0.11 per share for January, February, and March 2024, as well as a special distribution of $0.05 per share for December 2023. Since its IPO in 2010, Horizon has paid a total of $237 million in distributions to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
none
Rhea-AI Summary
Horizon Technology Finance Corporation (NASDAQ: HRZN) announced its financial results for Q3 2023. Net investment income per share was $0.53, NAV per share was $10.41. The debt portfolio yield was 17.1%. The portfolio grew by 15% YoY to $729 million. The Horizon Platform ended the quarter with a committed backlog of $222 million, including $202 million in HRZN commitments. Regular monthly distributions totaling $0.33 per share through March 2024 and a $0.05 special distribution payable in December 2023 were declared.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
-
Rhea-AI Summary
Horizon Technology Finance Corporation plans to release financial results for Q3 2023 on October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
The 26th BioFlorida Annual Conference highlighted the growth and success of Florida's life sciences industry. The conference featured discussions on various topics including medical innovations, advancements in neurodegeneration, and financing insights. BioFlorida also announced a strategic partnership with BIOQuébec. The conference recognized individuals and organizations for their achievements and presented awards in different categories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
Rhea-AI Summary
Horizon Technology Finance Provides Q3 2023 Portfolio Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags

FAQ

What is the current stock price of Horizon Technology Finance Corporation (HRZN)?

The current stock price of Horizon Technology Finance Corporation (HRZN) is $9.17 as of November 15, 2024.

What is the market cap of Horizon Technology Finance Corporation (HRZN)?

The market cap of Horizon Technology Finance Corporation (HRZN) is approximately 329.8M.

What is Horizon Technology Finance Corporation's primary business?

Horizon Technology Finance Corporation provides structured debt products to venture capital-backed companies in the technology, life sciences, healthcare information and services, and sustainability industries.

How much has Horizon invested in venture loans since its inception?

Since 2004, Horizon has originated and invested over $1.2 billion in venture loans to more than 200 growing companies.

Where is Horizon Technology Finance Corporation headquartered?

Horizon Technology Finance Corporation is headquartered in Farmington, Connecticut.

What is the company's investment objective?

Horizon aims to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives.

What were Horizon's total investment income and annualized yield for Q4 2023?

For Q4 2023, Horizon's total investment income was $28.2 million with a dollar-weighted annualized yield on average debt investments of 16.8%.

How does Horizon manage its investment risk?

Horizon actively manages its investments by supporting borrowers, maximizing capital recovery, and prudently growing its debt investment portfolio.

What recent acquisition did Horizon facilitate through HIMV LLC?

Horizon facilitated the acquisition of the entire portfolio of discovery, preclinical, and clinical stage assets of IMV Inc. by BioVaxys Technology Corp.

What are the declared distributions for the first quarter of 2024?

Horizon declared monthly distributions of $0.11 per share for April, May, and June 2024, and a special distribution of $0.05 per share in April 2024.

What are the net assets and NAV per share for Horizon as of December 31, 2023?

As of December 31, 2023, Horizon's net assets were $324.0 million, or $9.71 per share.

How does Horizon support its portfolio companies?

Horizon provides debt capital, leverages industry knowledge, and maintains strong relationships within the venture capital community to support the growth and success of its portfolio companies.

Horizon Technology Finance Corporation

OTC:HRZN

HRZN Rankings

HRZN Stock Data

329.80M
36.06M
1.27%
6.18%
2.15%
Asset Management
Financial Services
Link
United States of America
FARMINGTON